Cell And Gene Therapies Are Driving M&A Deal Activity

Law360 (March 18, 2020, 4:34 PM EDT) -- There have been remarkable advances over the last several years in the development of cell and gene therapies, or CGTs. These therapies represent truly groundbreaking approaches to the treatment and prevention of diseases, many of which have proven resistant to traditional drugs or therapies.

Cell therapy generally refers to the transfer of live cells into a patient to treat a disease. The cells may originate from the patient (autologous therapy), where they are extracted, modified and reinfused into the patient, or from a donor (allogeneic therapy). Gene therapy involves a change in the genetic code of a patient by inserting or...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!